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BACKGROUND 
Polyps in the gastrointestinal tract  
Polyps in the gastrointestinal (GI) tract are defined as nodules or 
masses that project above the level of the surrounding mucosa. 
Polyps are most common in the colon but can be found throughout 
the GI tract and at extraintestinal sites. The prevalence of polyps in 
the general population is unknown as polyps may be asympto-
matic. Autopsy studies suggest that about 30-60% of adults have 
colonic polyps (1-3). GI polyps vary in size from a few millimetres 
to several centimetres in diameter and can be described according 
to their gross structure: Pedunculated (with a stalk) or sessile 
(without a stalk). They may also be classified as non-neoplastic or 
neoplastic based on their histopathological appearance. The most 
common types of polyps in the large bowel are hyperplastic polyps 
and adenomas (1, 2, 4), the latter considered as having the poten-
tial to progress to cancer (neoplastic). The inflammatory polyp, 
which is characterized by fibromuscular hyperplasia of the lamina 
propria, mixed inflammatory infiltrates, erosion, and epithelial hy-
perplasia, is rare (5). 
 
Hamartomatous polyps 
The hamartomatous polyp (HP) is also rare. It is considered to be a 
non-neoplastic tumour-like growth consisting of normal tissue and 
normal mature cells in abnormal number or distribution. It can oc-
cur anywhere in the body, and whereas malignant tumours contain 
poorly differentiated cells, HPs consist of distinct cell types. HPs in 
the GI tract can be subdivided into different histopathological cat-
egories based on their histopathological appearance: the juvenile 
polyp (JP) and the Peutz-Jeghers polyp (PJP). Some also mention 
HPs related to ganglioneuromatosis and HPs of Cronkhite-Canada 
type (6). The JP was first reported by Diamond in 1939 (7) and Hel-
wig in 1946 (8), and the histopathological distinction to adenomas 
was finally described by Horrilleno et al. in 1957 (9). Macroscopi-
cally, JPs are typically lobulated and pedunculated with surface 
erosion and may vary in size from a few millimetres to several cen-
timetres (10). Histopathologically they appear cystic with dilated 
glands with inflammatory cells (Figure 1A and 1B). The PJPs are typ-
ically large and pedunculated with a lobulated shape with sizes that 
vary from few millimetres to several centimetres (Figure 3). They 
are histopathologically characterized by an arborizing network of 
smooth muscle, lamina propria, and glands lined by a normal ap-
pearing epithelium (5) (Figure 2). Although, the different subtypes 
of HPs and other GI polyps are well characterized, it can be difficult 
to distinguish them from each other at histopathological examina-
tions. Especially inflammatory polyps and JPs can resemble each 
other.  
 
Frequency and localization of hamartomatous polyps 
The JP is considered rare in the general population, but the exact 
prevalence is difficult to determine, as some polyps may be asymp-
tomatic throughout life. Yet, the JP is the most common type of 
polyp in children comprising over 90% of polyp cases (11-13). JPs 
are mainly found in the rectosigmoid, but are also localized in the 
remaining part of the colon in a significant amount of cases (14-
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17). Most patients have a single JP (17, 18), but patients with mul-
tiple polyps can have Juvenile Polyposis Syndrome (JPS) as de-
scribed later. The PJP is even more rare and can be found through-
out the GI tract, but mainly in the small bowel as part of the Peutz-
Jeghers Syndrome (PJS). Cases of solitary PJPs without additional 
symptoms of PJS have been described in few cases (19-21), but 
whether a single PJP is a clinical entity distinct from PJS is not clear 
at the moment (22).  
 
 
 
Figure 1: A: Histopathological image of a JP from a patient with a single JP. 
Note the cystic appearance. Magnification x10. B: Histopathological image 
of a JP from a study patient (Paper VI, Family III, Patient no.1) with JPS and 
a germline SMAD4 mutation. There is no clear difference in appearance be-
tween sporadic JPs and those appearing in JPS, but the syndromic polyps 
have been described as having a non-expanded stroma and higher crypt 
density (23). Magnification x10. 
 
Symptoms  
The symptoms reported in patients with JPs include rectal bleed-
ing, abdominal pain, anal extrusion of the polyp, anaemia, diar-
rhoea, and/or constipation. Rectal bleeding has been reported as 
the most frequent symptom and is seen in over 90% of cases (13, 
24). Most JPs in children are diagnosed in the first decade of life 
with a mean age of approximately five years, but can be diagnosed 
throughout childhood and adolescence (25-30). JPs in adults are 
less investigated: Roth&Helwig reported 59 adults with JPs with a 
mean age of 25.5 years and with rectal bleeding as the most com-
mon symptom, followed by prolapse and abdominal pain (31). 
Nugent et al. studied JPs in both adults and children and found a 
mean age at diagnosis of 32 years (32). For PJPs the presenting 
symptom can be small bowel obstruction, which is seen as the pre-
senting symptom in 40-50% of patients with PJS (33). Other symp-
toms include abdominal pain and rectal bleeding. The age at first 
GI symptom in PJS patients varies considerably, but the median age 
has been reported to be in adolescence, at 12-15 years of age (34, 
35). Importantly, mucocutaneous pigmentations, usually located in 
and around the mouth and nostrils, often precede the first GI 
symptoms. 
 
 
 
Figure 2: Histopathological image of a PJP from a study patient with PJS. 
Note the chracteristic arborizing network of smooth muscle. Magnification 
x2  
 
Clinical management  
The clinical management of polyps vary according to their localiza-
tion and size. Polyps in the large bowel are often detected using 
endoscopy and removed with polypectomy concurrently. Gastric 
or duodenal polyps are removed concurrently with gastroscopy. 
For patients, who need surveillance of the stomach, duodenum, 
and/or the large bowel, endoscopy is the method of choice as well. 
Surveillance and removal of polyps in the small bowel are espe-
cially relevant in PJS patients, but is complicated. Video Capsule 
Endoscopy (VCE) has proven to be a good method for detection of 
PJPs, but the detection rate and visualization of the entire small 
bowel may not be complete (36-38). An alternative to VCE is MR 
enterography (MRE), which has been studied in PJS patients (39-
41). One study showed that the accuracy of polyp localization and 
size was better with MRE compared to VCE, but that VCE detected 
smaller polyps more often (40). Yet, the detection rate for polyps 
> 10-15 mm has been reported to be the same (39, 40), or better 
with VCE compared to MRE (42). Patients are also reported to pre-
fer VCE to MRE (39, 42).  
Ideally any visualized polyp should be removed to prevent compli-
cations. Push-enteroscopy has for long been the preferred 
method, but the depth of insertion is limited. Thus Device-assisted 
enteroscopy, including double-balloon enteroscopy, single-balloon 
enteroscopy, spiral enteroscopy, and balloon-guided endoscopy, 
has largely replaced push-enteroscopy, but is more labour-inten-
sive (43). Studies have described a high diagnostic yield with suc-
cessful polypectomy when using double-balloon enteroscopy in 
PJS patients (44). Guidelines from The European Society of Gastro-
intestinal Endoscopy, recommend small bowel surveillance in PJS 
patients with VCE and/or MRE/enteroclysis, depending on local 
availability, expertise, and patient preference; they also recom-
mend Device-assisted enteroscopy with polypectomy when large 
polyps (> 10 -15 mm) are detected (43). An acute clinical presenta-
tion in the course of invagination or other complications often re-
sult in laparotomy with removal of the affected part of the bowel. 
 
 
Figure 3: Macroscopic appearance of PJPs in a study patient with PJS  
 
Single juvenile polyps and risk of cancer 
The risk of cancer when having one or a few JP(s) is not clear. Gen-
erally, it is believed that a single or a few JP(s) do not increase the 
risk of cancer and do not require clinical follow-up. This assumption 
is based on few studies with a limited number of patients, thus 
Nugent et al. studied the survival rate and cancer occurrence in a 
population of 82 patients with solitary JPs and found no increased 
risk of cancer (32). Kapetanakis et al. investigated cancer occur-
rences in relatives of 24 children with a single JP and found no in-
creased risk of more polyps or colorectal cancer (CRC) (45). Adeno-
matous transformations of single JPs have been reported (16, 46, 
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47), but no evidence-based practice guidelines exist for patients 
with one or a few JPs, who do not fulfil the criteria for JPS. 
 
Hamartomatous Polyposis Syndromes 
It is important to distinguish patients with one or a few HPs from 
patients with Hamartomatous Polyposis Syndromes (HPS). These 
patients typically have multiple HPs in the GI tract, a high risk of 
cancer from early age, and, sometimes, extraintestinal findings. 
The HPS account for only a small part of the inherited GI cancer 
syndromes and occur at approximately 1/10th of the frequency of 
adenomatous polyposis syndromes comprising <1% of CRC cases 
(48). The HPS include PJS, JPS, and the PTEN hamartoma tumour 
syndrome (PHTS). A high frequency of HPs has been reported in 
other syndromes, but these often have other features leading to 
the diagnosis. The syndromes include Gorlin Syndrome, Neurofi-
bromatosis type 1, Hereditary Mixed Polyposis Syndrome, Multiple 
Endocrine Neoplasia type 2B, and Cronkhite-Canada Syndrome. 
Comprehensive reviews of the HPS have been published (48-53). In 
the following sections the syndromes will be briefly described. 
 
Genetics and diagnostics of HPS 
HPS are, with the exception of Cronkhite-Canada syndrome, inher-
ited syndromes with an autosomal dominant inheritance pattern 
and age dependent penetrance. Diagnosis of HPS is usually based 
on a clinical approach, as clinical criteria for most HPS are available 
(52), and genetic testing is used frequently to confirm the diagno-
sis. When a patient has the characteristic clinical features as well 
as typical and numerous polyps, the diagnosis is often straightfor-
ward. Yet, the syndromes do share a phenotypic overlap and show 
significant inter- and intrafamiliar variation in expression, which 
can make diagnostics difficult. Furthermore, a significant part of 
HPS cases is sporadic (de novo) without affected family members. 
Candidate genes for most of the syndromes have been identified, 
but mutations cannot be detected in all patients with the syn-
dromes; thus a genetic screening of HPS related genes cannot rule 
out the diagnosis. Still, all patients suspected of HPS should be of-
fered genetic counselling in order to identify at-risk family mem-
bers and receive information about prenatal options.  
 
Peutz-Jeghers Syndrome 
PJS (OMIM 175200) was first described by JT Connor and 
Hutchinson in 1885 and 1886 respectively (54, 55). The syndrome 
is named after Peutz, who described a family with autosomal dom-
inant inheritance of GI polyposis and pigmented mucous mem-
branes in 1921 (56) and Jeghers who defined the syndrome as a 
clinical entity (57). The syndrome is characterized by GI polyposis 
with PJPs (especially in the small bowel) and mucocutaneous pig-
mentations (see Figure 4). There is not definite international con-
sensus about the clinical criteria, but Beggs et al. described a some-
what European consensus on behalf of a group of European 
experts (58). According to this paper a patient should fulfil one or 
more of following: (1) Two or more histologically confirmed PJS-
type HPs, (2) any number of PJS-type polyps detected in one indi-
vidual, who has a family history of PJS in a close relative(s), (3) char-
acteristic mucocutaneous pigmentations in an individual who has 
a family history of PJS in a close relative(s), (4) any number of PJS-
type polyps in an individual who also has characteristic mucocuta-
neous pigmentations (58).  
The incidence of PJS is estimated to be 1:50,000 to 1:200,000 live 
birth (59). The first GI symptoms can present in infancy or child-
hood and 50-75% of patients experience GI symptoms before 20 
years of age (34, 35), often preceded by mucocutaneous pigmen-
tations. The most common GI symptoms are obstruction of the 
small bowel, abdominal pain, and rectal bleeding, with obstruction 
occurring in over 50% of patients before adulthood (33, 60). Sev-
eral papers have discussed the natural history (33, 34, 61) and sur-
veillance programmes, especially the question of small bowel sur-
veillance (see also section 1.5) (58, 62, 63). Efforts have also been 
made to clarify possible genotype-phenotype correlations, but the 
results have not been consistent (35, 64-66). The risk of cancer has 
been assessed in studies with larger study populations (64, 67, 68). 
These studies have demonstrated a high, age-dependent risk of not 
only GI cancer but also extraintestinal cancer, especially testicular 
cancer, gynaecological cancers, and breast cancer. Germline muta-
tions can be found in STK11, a gene consisting of nine coding exons 
and one non-coding exon. STK11 mutations are detected in more 
than 90% of patients fulfilling the clinical criteria (69). Approxi-
mately 50% of the patients are de novo cases (34). The high risk of 
cancer in different organs leads to a rationale of a somewhat ex-
tensive surveillance program. This should at least include surveil-
lance of the breast, cervix, GI tract, and testes, while surveillance 
of the ovaries and pancreas is debated (58, 62). 
 
 
 
Figure 4: Characteristic mucocutaneous pigmentations on the lips and the 
oral cavity of a PJS patient. With permission from Professor Flemming 
Skovby, Department of Paediatrics, Roskilde Hospital, Denmark.  
 
Juvenile Polyposis Syndrome  
JPS (OMIM 174900) was first recognized as a clinical entity in the 
mid 1960es (70). The syndrome is characterised by multiple JPs 
throughout the GI tract, but mainly in the colon, rectum, and ven-
tricle. The incidence is estimated to be approximately 1:100,000 
(50). The widely used clinical criteria is based on those suggested 
by Jass et al.: (1) The findings of more than five JPs in the colon or 
rectum, and/or (2) multiple JPs throughout the GI tract, and/or (3) 
a JP together with a family history of JPS (71). Compared to PJS, the 
natural history and cancer risk estimates are less well investigated. 
The GI symptoms are mainly rectal bleeding, as with patients with 
a single JP, but can also be prolapse of the polyp, melena pain, di-
arrhoea, and/or anaemia (72). The risk of CRC and gastric cancer is 
reported to be high in several studies, yet the estimates vary: 
Brosens et al. calculated a cumulative life-time risk for CRC to be 
38.7% (73), while Howe et al. found that 38% of a JPS kindred had 
CRC and 21% upper GI cancers. As with other inherited cancer syn-
dromes the cancers seem to develop at a young age with a mean 
age reported to be around 40 years of age (74). Pancreatic cancer 
and cancer in the small bowel appear to be rare (74). Germline mu-
tations are detected in SMAD4 and BMPR1A in 20-30% of cases re-
spectively, which leaves approximately 40-60% of JPS patients 
without a known genetic cause (75-78). Approximately 50% of af-
fected patients have a positive family history (79).  
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Previous studies, before the era of molecular diagnostics, have re-
ported JPS patients with symptoms of hereditary haemorrhagic tel-
angiectasia (HHT), which include epistaxis, telangiectasias, and AV-
malformations, mainly pulmonary (80, 81). Later studies have con-
firmed that patients with SMAD4 mutations can have symptoms of 
both conditions (82-85), and the syndrome is now referred to as 
the JP-HHT syndrome (OMIM 175050). In addition, cases of aortic 
root dilatation have been described in patients with SMAD4 muta-
tions (86, 87). The AV-malformations in the lungs, GI tract, liver, 
and brain in JP-HHT patients can cause severe bleeding and poten-
tially be life threatening. Moreover, gastric polyposis seems to be 
more frequent compared to BMPR1A mutations carriers (88-90).  
The rationale for surveillance in JPS patients is based on the high 
risk of CRC and gastric cancer, and to avoid morbidity in relation to 
polyposis. As the clinical picture varies, so does the clinical ap-
proach: In some patients continuous endoscopic polypectomies 
will be sufficient, while others need a subtotal colectomy or gas-
trectomy. British guidelines for surveillance have been published in 
2009-10 (91) and American guidelines in 2015 (62). SMAD4 muta-
tions carriers require additional follow-up for HHT and aortopathy. 
Guidelines for HHT surveillance have been described by McDonald 
et al. (92) and Shovlin et al. (93).  
 
PTEN hamartoma tumour syndrome 
PTEN hamartoma tumour syndrome (PHTS, OMIM 601728) inclu-
des Cowden Syndrome (CS, OMIM 158350), Bannayan-Riley-Ru-
valcaba Syndrome (OMIM 153480), PTEN-related Proteus syn-
drome, and Proteus-like Syndrome. CS is the most common with a 
prevalence of approximately 1:200,000 individuals (94). The phe-
notypic spectrum of PHTS is wide and variably, and especially CS 
and Bannayan-Riley-Ruvalcaba Syndrome have a considerable phe-
notypic overlap. PTEN-related Proteus syndrome and Proteus-like 
syndrome are related to Proteus Syndrome, are very rare, and still 
rather undefined. The conditions are characterized by hamartoma-
tous overgrowth of multiple tissues and diagnosis is usually based 
on the phenotype. The syndromes are not discussed further here.  
 
Cowden Syndrome: CS is named after the patient Rachel Cowden, 
whose symptoms were described in a scientific paper in 1963 (95). 
She expressed several clinical features now recognized as typical of 
CS including mild mental retardation, multiple hyperkeratotic pap-
illomata, as well as fibrocystic disease of the breast. In general, CS 
is characterized by a wide range of symptoms caused by multiple 
hamartomatous lesions of the skin and mucous membranes. Yet, 
some symptoms are considered to be pathognomonic, see Table 1. 
Furthermore, cancer in the thyroid, breast, endometrium, and 
brain characterize CS. More than 90% of individuals with germline 
PTEN mutations are believed to have symptoms by the age of 20 
years, whereas nearly 100% have symptoms by the age of 30 years 
(96). Consensus diagnostic criteria for CS have been developed and 
are continuously updated (97), see Table 1. GI involvement, espe-
cially with polyps in the colon and rectum but also in the stomach, 
has been reported several times (98-101). The histology of the 
polyps is not solely HPs, but also adenomas and hyperplastic polyps 
as well as ganglioneurinomas. Heald et al. (99) found that GI polyps 
were reported in 51.2% of 127 individuals with PTEN mutations 
with 24 having both upper and lower GI polyps, and the authors 
argued for colonosocpy in the surveillance program (99). Studies 
including numerous patients with CS and/or PTEN mutations have 
demonstrated a high increased risk for cancer at various anatomi-
cal sites such as breast, thyroid, endometrial, colon, and renal car-
cinoma (102, 103). Germline mutations can be detected in PTEN 
with a mutation detection rate reported to be between 25-80% de-
pending on the inclusion criteria (96, 104). The proportion of de 
novo cases is unknown, but the de novo frequency of PTEN muta-
tions has been estimated to be 10-47% (105). Surveillance guide-
lines have been presented and discussed, but many follow the 
guideline from the National Comprehensive Cancer Network 
http://www.nccn.org/professionals/physician_gls/f_guide-
lines.asp. 
 
 
Table 1: The diagnostic criteria for Cowden Syndrome as reviewed by Eng. 
(106). Last updated February 2016. 
 
Bannayan-Riley-Ruvalcaba Syndrome 
Bannayan-Riley-Ruvalcaba Syndrome is characterized by macro-
cephaly, GI polyposis with HPs, lipomatosis, and pigmented mac-
ules of the glans penis. HPs have been reported in up to 45% of 
cases (107). Recommendations of surveillance have not been es-
tablished, but patients with PTEN mutations (~60% of patients with 
the syndrome) should undergo the same surveillance program as 
patients with CS (108).  
 
Other syndromes with hamartomatous polyps  
Hereditary Mixed Polyposis Syndrome (OMIM 601299): The syn-
drome is characterized by a mixed pattern of polyps in the large 
bowel, including HPs, hyperplastic polyps, and/or adenomas. CRC 
occurs in a high proportion of reported families (109). The syn-
drome has been mapped to the chromosomal region of 6q (110) as 
well as 10q23, which includes BMPR1A, and mutations in this gene 
have been found in a few families (111, 112). Jeager et al. mapped 
a causative gene to 15q13.3 and detected a duplication spanning 
from intron 2 in SCG5 gene to just upstream of the GREM1 locus 
(113). 
 
Gorlin Syndrome (or Basal cell nevus syndrome, OMIM 109400) is 
characterized by multiple basal cell carcinomas, childhood medul-
loblastoma, macrocephaly, frontal bossing, and palmar and plantar 
pits, as well as odontogenic keratocysts. Schwartz et al. described 
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multiple gastric HPs in patients with Gorlin Syndrome (114), but GI 
polyps are not a major feature and GI surveillance is not recom-
mended. Mutations are found in PTCH1, PTCH2, and SUFU. Inter-
national guidelines for surveillance has been published by Bree et 
al. (115) and we discussed these in a Danish context in 2015 (116).  
 
Neurofibromatosis type 1 (OMIM 162200) is characterized by mul-
tiple neurofibromas, multiple café au lait spots, iris Lisch nodules, 
as well as axillary and inguinal freckling. Most GI involvement is 
usually incidental and asymptomatic (48), but some suggest that 
approximately 25% of patients have GI stromal tumours (GISTs) 
(117). GI polyposis including ganglioneuromatosis has also been re-
ported (118), but the risk of GI cancer does not seem to be in-
creased (119). Neurofibromatosis type 1 has a prevalence of ap-
proximately 1:5000 and germline mutations are found in NF1 in 
~95% of patients. 
 
Multiple endocrine neoplasia type 2B (OMIM 162300) is one of 
three subtypes of the multiple endocrine neoplasia type 2 syn-
drome, the others being multiple endocrine neoplasia type 2A and 
familial medullary thyroid carcinoma. The syndrome is character-
ized by medullary carcinoma of the thyroid, pheochromocytoma, 
GI ganglioneuromatosis, and skeletal abnormalities. Diffuse GI gan-
glioneuromatosis is observed in up to 40% of patients (120). Muta-
tions in RET are detected in ~95% of patients. 
 
Birt-Hogg-Dubé (OMIM 135160): Cutaneous fibrofolliculomas, bi-
lateral pulmonary cysts, spontaneous pneumothorax, and renal tu-
mours characterize this syndrome. Early case reports linked colonic 
polyps and CRC with the syndrome (121), but the correlation is un-
clear. Zbar et al. did not find an increased risk for the development 
of colonic polyps or CRC in their study (122), whereas Nahorski et 
al. found an increased risk, though not significant, of CRC in pa-
tients compared to the general population (123). Mutations are 
detected in FLCN in ~90% of patients.   
 
Cronkhite-Canada syndrome is characterized by GI polyposis with 
HPs, enteropathy, and skin-manifestations. The syndrome appears 
to be an autoimmune inflammatory condition (124). 
 
The molecular functions of STK11, PTEN, BMPR1A, and SMAD4  
STK11 encodes the enzyme serine/threonine kinase and is re-
garded as a tumour suppressor gene. It has numerous functions 
and controls the activity of AMP-activated protein kinase (AMPK) 
family members; it thereby plays a role in various processes such 
as cell metabolism, cell polarity, apoptosis, cell cycle arrest, and 
cell proliferation (125). Importantly, STK11 downregulates the 
mammalian target of rapamycin (mTOR) pathway. The mTOR is a 
highly conserved kinase in all eukaryotes and is a central regulator 
of numerous cell activities. Numerous pathological conditions have 
been linked to the mTOR pathway, including both monogenetic 
conditions (Neurofibromatosis type 1 and Von Hippel-Lindau Syn-
drome) and multifactorial conditions such as obesity and type 2 di-
abetes. Specific targeted therapy, the mTOR inhibitors, has been 
developed, which have shown some benefits for patients with con-
ditions related to this pathway such as Tuberous Sclerosis (126).  
 
PTEN is widely expressed throughout the body and encodes the 
protein phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It 
is regarded as a tumour suppressor gene with multiple roles in cel-
lular regulation. Thus PTEN is involved in protein synthesis, cell cy-
cle, migration, growth, DNA repair, and survival signalling, and a 
defect or altered protein leads to deregulation of these processes 
(127). It has numerous functions, but notably it affects the mTOR 
pathway through downregulation of the PI3K/AKT pathway to in-
hibit cell survival, growth, and proliferation (128), see Figure 5.  
 
 
 
Figure 5: A simplified illustration of the effect of PTEN and STK11 on the 
mTOR pathway. The protein encoded by STK11 is activated by binding to 
the pseudokinase STRAD and the protein MO25. The complex is an active 
unit, which phosphorylates AMPK, which activate the protein TSC2 in order 
to downregulate mTOR. The protein encoded by PTEN is a downstream reg-
ulator of the PIP3/AKT1 pathway: A receptor on the cell surface is activated 
by growth factors. This will activate PI3K, which phosphorylates PIP2 to 
PIP3. PTEN inhibits this reaction and thereby negatively regulates the AKT 
and PDK1 dependent processes. For details on the molecular function of 
STK11 see Fan et al. (125) and Shaw (129). For details on PTEN function see 
Hopkins et al. (127). 
 
 
 
Figure 6: A simplified illustration of the TGF-β pathway in which SMAD4 and 
BMPR1A are involved. The signalling process begins when a member of the 
TGF-β family (in this case a BMP (orange squares)) binds to a type II receptor 
in this case BMPR2 (green) in the cell membrane. This activates a type I re-
ceptor (in this case BMPR1A (purple)), which then form a complex (130). 
This complex then activates the SMAD proteins (SMAD1, SMAD5, and 
SMAD8) called the R-SMADS (receptor regulated SMADs), which then bind 
a co-SMAD, SMAD4. SMAD4 mediates the translocation of the R-SMADs 
into the nucleus, where it acts as a transcription factor (131). Thus the 
SMAD proteins are central signalling molecules acting downstream of the 
type I and type II receptors, not only the BMPR1A and BMPR2 receptor, but 
also other receptors in this pathway. 
 
Both BMPR1A and SMAD4 encode proteins that work in the trans-
forming growth factor beta (TGF-β) pathway. This pathway is in-
volved in several cellular processes including cell growth, cell dif-
ferentiation, apoptosis, and cellular homeostasis. The pathway is 
activated when a ligand from the TGF-β superfamily binds to a Type 
 DANISH MEDICAL JOURNAL   6 
II receptor on the cell surface resulting in a cascade involving sev-
eral SMAD proteins, including SMAD4 (130), see Figure 6. BMPR1A 
encodes the protein bone morphogenetic protein receptor 1A, 
which is a Type I receptor. Other receptors in this pathway include 
BMPR2 (type II-receptor). The ligands of these receptors include 
bone morphogenetic proteins (BMPs), Activin, and other members 
of the TGF-β superfamily (131). Other genes encoding proteins 
working in the TGF-β pathway include ENG, which encode a mem-
brane glycoprotein, and ACVRL1, which encodes a type I receptor. 
Germline mutations in ENG and ACVRL1 are found in a majority of 
patients with HHT.   
 
The pathophysiological mechanisms of cancer development in 
PJS and JPS 
Both SMAD4 and STK11 are found to be somatically mutated in var-
ious types of sporadic cancer and are considered tumour suppres-
sors: Thus both loss of heterozygosity (LOH) and somatic mutations 
of SMAD4 have been found in mainly sporadic CRC and in pancre-
atic carcinomas (132, 133). Somatic mutations of STK11 accompa-
nied with LOH have been found in several types of sporadic cancers 
but mainly in non-small-cell lung cancer (134). Even though genes 
associated with HPS may play a role in sporadic cancer, what are 
the pathophysiological mechanisms of cancer development in pa-
tients with JPS and PJS, who are predisposed to cancer from birth? 
Does cancer develops by the same molecular sequences as in spo-
radic cancer? Does cancer develops through the HPs or coexisting 
adenomas? Although, the mechanisms still are largely unknown, 
some studies have tried to address these questions: 
In 1999 Bosman published the idea of a hamartoma-adenoma-car-
cinoma sequence as a pendant to the known adenoma-carcinoma 
sequence (135). This theory has since been debated. Bosman 
based his theory on a study where polyps from JPS patients were 
found to have a somatic 10q22 deletion in the lamina propria but 
not in the epithelial cells (136). Thus Bosman hypothesised that 
factors secreted by the stroma could drive the epithelial prolifera-
tion and be responsible for the induction of malignancy (135). This 
is the so-called landscaper defect: that the microenvironment sur-
rounding epithelial cells disturbs the epithelial architecture, differ-
entiation, and proliferation. Some studies have investigated this 
hypothesis, but without consistent results: Woodford-Richens et al. 
studied JPs from SMAD4 mutations carriers and found loss of 
SMAD4 in epithelial cells and some in the stromal cell (137), hence 
arguing against Bosmans theory of a landscaper effect. Other stud-
ies have also found LOH of both SMAD4 and BMPR1A in JPs and 
carcinomas from mutation positive JPS patients (138, 139). These 
studies as well as Woodford-Richens et al.’s study speak in favour 
of the hypothesis that a second hit of the wild-type allele initiates 
growth and neoplastic progression of JPS polyps. Yet, this was not 
supported by Blatter et al. who found no LOH of SMAD4 in 14 JPs 
in SMAD4 mutation carriers (140). In search of evidence for the ad-
enoma-carcinomas sequence in JPS patients, molecular alterations 
as observed in sporadic CRC, have been investigated in JPs and car-
cinomas from JPS patients: The results point towards that molecu-
lar alterations that is important in sporadic cancer development 
play a limited role in JPS patients, thus altered expression of β-ca-
tenin and p53, and mutations in APC and KRAS, have only been de-
tected in a few cases (23, 138).   
In PJPs, dysplastic, adenomatous, and carcinomatous changes have 
been observed but are relatively rare (59, 141-144), thus speaking 
against a hamartoma-adenoma-carcinoma sequence in PJS. Jansen 
et al. proposed that germline STK11 mutations lead to dysregula-
tion of cell polarity and mucosal prolapse, but the PJPs in them-
selves are not pre-malignant (145). This was somewhat supported 
by Korsse et al. who investigated PJPs and carcinomas from PJS pa-
tients and found LOH of STK11 in only three out of six GI carcino-
mas, and in the dysplastic epithelium in three out of five PJPs, but 
not in the non-dysplastic epithelium of the same polyps (144). 
Other studies have also detected LOH of STK11 in both PJS carcino-
mas and PJPs, but not in all (142, 146, 147). Concerning alterations 
as observed in sporadic CRC the results resemble what have been 
found in JPS: mutations affecting β-catenin in both PJS carcinomas 
and PJPs have been identified in a few cases (142, 144), whereas 
KRAS mutations, APC mutations, or 5q LOH are rarely detected 
(142, 144, 146, 148). Yet, Entius et al. dentified APC mutations in 
four of five PJS carcinomas (148). Altered p53 expression has also 
been reported in some cases (144, 146, 148).  
In conclusion, based on the presented papers, it is not possible to 
determine the exact mechanisms or the role of the HPs in cancer 
development in JPS and PJS. The pathophysiological mechanisms 
underlying cancer development in PHTS are to be unravelled as 
well. PTEN is frequently somatically mutated in various types of 
sporadic cancer, and LOH has been found in carcinomas establish-
ing PTEN’s role as a tumour suppressor (149). But as this thesis 
mainly focus on JPS and PJS, the mechanisms of cancer develop-
ment in PHTS are not discussed further here. 
 
Next generation sequencing 
Since the detection of various candidate genes in HPS, genetic anal-
yses have been used to assist the clinical evaluation. Just a few 
years ago, mutation analyses and sequencing of relevant genes 
were performed with Sanger sequencing as method of choice. 
Though the method is accurate, it is limited by cost, speed, and 
sample size. But in 2005 DNA sequencing technology took a giant 
leap forward, when the first Next generation sequencing (NGS) in-
strument was introduced (150). NGS (massive parallel sequencing 
or high-throughput sequencing) have revolutionized the sequenc-
ing process. The analyses performed with NGS can be divided in 
three subgroups: Whole genome sequencing, where the whole ge-
nome, both the coding and non-coding regions, is sequenced, 
Whole exome sequencing (WES) where the entire coding region is 
sequenced, and targeted next generation sequencing (targeted 
NGS), where exons in selected genes e.g. in a 200 gene panel, are 
sequenced. Whether one uses Whole genome sequencing, WES, or 
targeted NGS depends on the purpose of the analysis as well ethi-
cal and financial considerations.  
In the beginning of this research project, NGS was just being imple-
mented in the genetics labs in Denmark, but it is now the method 
of choice when performing genetic sequencing in many cases, and 
it has been shown that targeted NGS equals the quality of Sanger 
sequencing (151). The advantages in NGS are numerous: whereas 
several strands of template DNA was needed in Sanger sequencing, 
in NGS, in principle, a sequence can be obtained from a single 
strand. NGS is also less time consuming, as is it massively parallel, 
allowing multiple base positions to be read in a single run. The re-
duced time, manpower, and reagents in NGS leads to much lower 
costs per base (152). In other words, had we used Sanger sequenc-
ing to investigate the 26 genes in 77 patients (Paper III), the project 
would have taken much longer to conduct.  
The most challenging part of NGS is handling the huge amount of 
generated genetic data. Even targeted NGS, where “only” a panel 
of genes is sequenced, generates information on a large number of 
personal genetic variants, which have to be interpreted. The key 
question is how to separate non-clinical relevant variants, e.g. 
common variants, from those of importance. There are no golden 
standard to this bioinformatics approach and the method differs 
between labs and between research groups. The technical details 
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of NGS, the bioinformatics pipeline, and our approach to evaluat-
ing the detected variants in Paper III are discussed later. 
 
Ethical considerations when performing Next generation se-
quencing 
The increasing use of NGS in both research and in clinical settings 
has led to a passionate debate on several ethical questions, which 
arise from the possibility of sequencing the whole or larger part of 
the genome. When The Regional Scientific Ethical Committees for 
Southern Denmark approved our research protocol, NGS was still 
a rather new technique, and the committees did not yet have offi-
cial guidelines on the specific ethical issues concerning NGS. 
Though some had discussed the ethical implications (153, 154), it 
was not until 2013 that the American College of Medical Genetics 
published their guidelines (155) – a year later than the approval of 
our study. We initially got the approval for doing both WES and 
targeted NGS on DNA from patients with one or more HPs (Paper 
III) and we were faced with the ethical considerations as presented 
in Figure 7. In the following I will describe one of them: the issue 
concerning incidental findings, which we choose to address in Pa-
per IV. 
 
Incidental findings: The “opting out” possibility 
One of the most discussed issues has been the risk of detecting one 
or more incidental findings (IFs), defined as: ”A finding concerning 
an individual research participant that has potential health or re-
productive importance and is discovered in the course of conduct-
ing research but is beyond the aims of the study” by Wolf et al. 
(156). In other words during NGS, where several genes or the 
whole exome is sequenced at the same time, the researchers and 
clinicians may stumble upon genetic variants of significance not re-
lated to the clinical/research question i.e. the finding of a cancer 
predisposing mutation in a child evaluated for mental retardation. 
One of the most discussed aspects on IFs has been on whether the 
patients/participants should be offered the possibility of not being 
informed about IFs, the so-called “opting out” possibility. The 
guidelines from the American College of Medical Genetics in 2013 
did not recommend that patients should have this option (155), 
which caused a response from several clinicians and researchers 
arguing that in respect for patient autonomy and to avoid medical 
paternalism the possibility should exist (157-160). The counterpart 
argued that the patients and relatives could have an interest in 
knowing of IFs as they can potentially lead to treatment or preven-
tion of disease, and that the duty to prevent harm supersedes con-
cerns about autonomy (161, 162). The American guidelines have 
since then been revised to agree that patients could opt out of re-
ceiving these types of results (163). The recommendation from the 
European Society of Human Genetics (ESHG) from 2013 also dis-
cusses the opting out possibility and states that a patients’ right 
not to know, does not automatically override professional respon-
sibilities when the patient’s own health or that of his or her close 
relatives are at stake (164). We too faced the key question as how 
to approach the possibility of IFs in our patient group and whether 
they should have the possibility of opting out. As the research in 
this field was quite new at the time we conducted a small study on 
what the research participants actually wanted to know (Paper IV).  
 
 
Figure 7: Ethical questions arising when performing NGS. Highlighted in red 
is the question we choose to address in Paper IV. 
 
AIMS 
The primary aim of the study was to expand the knowledge on clin-
ical course and molecular genetics in patients with hamartomatous 
polyps and the Hamartomatous Polyposis Syndromes. In addition, 
we decided to investigate research participants’ attitude towards 
the results of extensive genetic testing. Thus we designed six stud-
ies with the following aims:      
 
1) To describe the occurrence of hamartomatous juvenile polyps in 
the Danish population.  
 
2) To review the current literature on the Hamartomatous Polypo-
sis Syndromes 
 
3) To investigate whether patients with ≤5 hamartomatous polyps 
in the large bowel have a pathogenic germline mutation in the 
Hamartomatous Polyposis Syndrome-associated genes when using 
Next generation sequencing.  
 
4) To investigate research participants’ attitude towards disclosure 
of incidental genetic findings in Next generation sequencing-stud-
ies.  
 
5) To identify Danish patients with a Hamartomatous Polyposis 
Syndromes, including 1) Peutz-Jeghers Syndrome and 2) patients 
with Juvenile Polyposis Syndrome and pathogenic SMAD4 muta-
tions, and gather genetic and clinical information to further char-
acterize the genotype and phenotype of these two patient groups.  
 
METHODOLOGICAL CONSIDERATIONS 
In the following sections I will describe the methodological consid-
erations for Paper I-VI including strengths and limitations of the 
methodology.  
 
Methodological considerations: Paper I 
The aim of Paper I was to describe the occurrence of JPs in the Dan-
ish population from 1995-2014. For this purpose we used infor-
mation on registered JPs in the Danish Pathology Data Bank 
(DPDB). The DPDB was also used as part of the methods in Paper 
III-VI.  
 
Danish Pathology Data Bank: Quality of Data  
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As Paper I is solely based on data from DPDB the quality of this 
database is crucial: The DPDB contains detailed nationwide records 
of all pathology specimens analysed in Denmark. The register can 
be considered to be complete since 1997, but it also comprise rec-
ords from several departments before that (the list can be seen on 
the website for DPDB: http://www.patobank.dk/in-
dex.php?ID=16&lang=da) (165). Searches in DPDB can be made 
with different modalities as the DPDB is build on a Danish version 
of Systemized Nomenclature of Medicine (SNOMED) codes (166). 
In our case the central administration office of DPDB provided the 
data (Search on SNOMED: “M75640 Juvenile polyp” from 1995-
2014 with supplementary codes specifying the anatomic localiza-
tion of the large bowel).  
 
Why DPDB?  
The DPDB provides an excellent opportunity to conduct research 
and has been reviewed in a few papers, which state that the cov-
erage of the DPDB is high and nearly 100% (165, 166). When any 
evaluation at a Danish department of pathology is finished, the his-
topathological diagnoses and description are automatically sent 
online to the DPDB. Every patient in Denmark is provided with a 
social security number, which is noted together with the histo-
pathological data; this allows for additional searches in other reg-
isters, such as medical files etc. And probably there is no other way 
of investigating the occurrence of JPs in Denmark, as the ICD-10 
codes used by clinicians are often more broad i.e. “unspecified 
polyp” or “rectal polyp.” 
 
Limitations 
As with all registers, miscoding cannot be ruled out, and in the be-
ginning of the period the register was not entirely complete. Fur-
thermore, we cannot be sure that the JPs in some cases were 
coded as HPs (SNOMED: M75630), but based on the results from 
Paper III we estimate this to be rare. In Paper III almost all polyps 
coded as HPs in the DPDB were sporadic gastric fundic gland polyps 
in the stomach. The histopathological difficulties in separating JPs 
from other types of polyps have been described in several studies, 
which report a significant interpathologist discrepancy in the diag-
nostic evaluation (32, 75, 167). In order to determine a more pre-
cise prevalence/incidence of JPs one would have to re-evaluate all 
JPs to confirm the diagnoses. Furthermore, a study like this only 
tells us about detected polyps, thus we cannot determine the exact 
prevalence of JPs as some polyps can be asymptomatic throughout 
life. Moreover, we do not know the manner of polyp removal (co-
lonoscopy, sigmoideoscopy, surgery, or others) and the identified 
patients can have more polyps. Finally, the accuracy of the recur-
rence rate is limited by the study period. 
 
Strengths 
To our knowledge a study on Danish JPs in both children and adults 
has not been performed previously. The strength of our study is 
the quality of the data from DPDB, which allows us to assume that 
almost all removed JPs are recorded here.  
 
Methodological considerations Paper II 
The aim of Paper II was to conduct a review of the HPS based on 
the current literature. 
 
Limitations 
We used a systematic approach to identify relevant studies, yet we 
did not include all studies, or systematically evaluate the methods 
of the included studies. Most studies of HPS are small cohorts stud-
ies or case reports, which can be subjected to publication bias, as-
certainment bias, and referral bias, and thus not give a accurate 
picture of the syndromes e.g. the phenotype, genotype, or the es-
timation of cancer risk. Thus, this review may not be as transparent 
as a completely systematic review or meta-analysis.  
 
Strengths 
Even though the approach was not completely systematic, the re-
view can be useful as an overview, to form the basis for further 
studies, and to increase awareness of the syndromes.  
 
Methodological considerations: Paper III 
In Paper III we investigated whether patients with five or less HPs 
in the large bowel had a pathogenic germline mutation in HPS as-
sociated genes. If this hypothesis was correct one could use genetic 
testing to diagnose HPS when the first HP gives symptoms, and 
thereby be able to offer relevant surveillance to the patient and at 
at-risk family members. In the following I will elaborate on the en-
rolment of patients, the genetic technique, and evaluation of the 
detected genetic variants. 
 
Identification and inclusion of patients  
Patients with HPs were identified through the DPDB. We searched 
on the SNOMED codes: Hamartomatous polyp: M75630, Peutz-
Jeghers Syndrome: S54320, and Juvenile polyp: M75640. The 
search was initially nationwide, but only patients whose polyps 
were evaluated in the Region of Southern Denmark were offered 
participation. Patient/parents/guardians consented in writing after 
written and oral information. We wanted to include patients of a 
wide age-span, as the age of diagnosis and presentation of HPS are 
reported to be wide. Thus we included patients aged 0-80 years. 
Yet, one could hypothesise that the risk of detecting yet undiag-
nosed HPS in children would be higher as they have not had many 
years of developing additional symptoms. We did not systemati-
cally ask for family history of cancer or other diseases at inclusion, 
so the first part of the study was solely based on the phenotype of 
the polyp(s). After genetic analysis, we were allowed to contact the 
involved families and ask for further clinical information or addi-
tional blood samples from family members if necessary.  
 
Sporadic gastric fundic gland polyps   
We initially choose to enrol patients with HPs in both the upper 
and lower GI tract. But when looking closer at the medical files of 
those with HPs in the stomach, it was revealed that they had spo-
radic gastric fundic gland polyps, which were coded as HPs in DPDB. 
Sporadic gastric fundic gland polyps are one of the most common 
types of gastric polyps and have been found in up to 2% of all en-
doscopic studies (168). Their association to CRC and gastric cancer 
has been studied: Genta et al. found an association to colonic ade-
nomas, but only in women, and not to CRC, whereas Cimmino et 
al. did not find an association to adenomas (169, 170). Moreover, 
sporadic gastric fundic gland polyps are linked to the use of proton 
pump inhibitors (171). A large part of patients with Familial Adeno-
matous Polyposis has gastric fundic glands polyps, but no relation 
to the HPS has been described. Thus, these patients were excluded, 
and at the end only patients with HPs in the large bowel partici-
pated in the study.  
 
Why targeted NGS? 
The Regional Scientific Ethical Committees for Southern Denmark 
initially approved the use of both WES and targeted NGS in our 
study. Thus we enrolled patients with the purpose of doing exten-
sive genetic analysis and the patients were informed accordingly. 
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In the end we choose to perform targeted NGS as it gives a much 
higher coverage of the genes of interest and reduces sequencing 
cost and time. Furthermore, the coverage pr. base is 200-1000x or 
even higher, which makes it possible also to analyse for larger de-
letions and duplications. 
 
Creation of the gene panel 
The design of the gene panel is described in Paper III. In addition to 
HPS-associated genes we included genes, which are not directly re-
lated to HPS, such as CDH1 and APC. This was partly because the 
NGS gene panel was to be integrated in the clinic, but also because 
we wanted to have a broad view of the genetic changes in genes 
related to GI cancer. Giving the rather broad gene panel there was 
still a small risk of detecting IFs, although the risk was significantly 
reduced compared to WES. 
 
NGS step by step  
In this section, I will describe, though not in complete details, the 
more technical aspects of the NGS analysis. This is to aid in the un-
derstanding of the strengths and limitations of the method. Several 
NGS platforms are available on the market, but as we used the Il-
lumina Sequencing by Synthesis Chemistry on the Illumina HiSeq 
1500 platform, this approach is described here, see also Figure 8, 
Picture 1-9:  
 
1) Library preparation (Picture 1 in Figure 8): DNA is fragmented 
into fragments of approximately 200 bp with random breakpoints. 
The fragments are ligated with a 5’ and 3’ adapters and PCR-ampli-
fied. At this point, WES and targeted sequencing require an addi-
tional step of capturing where the desired regions of the genome 
are selected. Capture is performed by hybridization of target spe-
cific probes (or baids) to the adaptor-ligated fragments. The baids 
are short RNA biotinylated oligonucleotides. Due to the biotin la-
bel, hybridized fragments can be selected using magnetic streptav-
idin conjugated beads. To perform capturing different versions of 
capture kits have been developed. They vary by probe, design, and, 
accordingly, specificity of the target region. In this study we used a 
custom designed capturing method by Agilent SureDesign 
http://www.genomics.agilent.com/article.jsp?pageId=3083). For 
illustration of capturing, see this webside.  
 
2) Cluster generation (Picture 2-6 in Figure 8): The library, now con-
taining the genomic regions of interest, is then loaded into a flow 
cell (glass slide with lanes) where fragments are captured on a lawn 
with two types of surface-bound oligos complementary to the li-
brary adapters (Picture 2). The free end of a ligated fragment then 
folds to forms a bridge as it hybridizes to a complementary oligo 
on the surface (Picture 3). A DNA polymerase then produces the 
complementary strand, and thus creating a double stranded 
bridge, which is then denatured (Picture 4-5). The result is two cop-
ies of the original DNA-fragment, which are attached to the flow-
cell. This process is then repeated, and each fragment is amplified 
into distinct, clonal clusters through bridge amplification (Picture 
6). When cluster generation is complete, the reverse strand is re-
moved leaving several copies of the forward strand to be se-
quenced.  
 
3) Sequencing (Picture 7-8 in Figure 8): Single fluorescent dNTPs are 
then incorporated into the DNA template strands with DNA poly-
merase (Picture 7). The first cycle consists of incorporation of a sin-
gle fluorescent nucleotide followed by high-resolution imaging, 
where nucleotides are identified by fluorescent emission (Picture 
8). This is repeated for the second base etc. Thus every position of 
the sequence is read. The critical difference to Sanger sequencing 
is that, instead of sequencing a single DNA fragment in one reac-
tion, NGS extends this process across millions of fragments in a 
massively parallel fashion.  
A skilled laboratory technician performed our library preparation, 
cluster generation, and sequencing.  
 
 
Figure 8: Illustration of NGS with Illuminas Sequencing by Synthesis Chem-
istry. Picture 1: Library preparation. Picture 2-6: Bridge amplification and 
cluster generation. Picture 7-8: Incorporation of fluorescent nucleotides 
and imaging of the sequence. Picture 9: Alignment to the reference ge-
nome. Pictures are Courtesy of Illumina, Inc. www.illumina.com 
 
Data analysis  
The result from NGS is several fragmented reads of sequences, 
which have to be “translated” into a file format, which lists the ge-
netic variants of the patient, so we can interpret them. This bioin-
formatic stepwise analysis of data is crucial, yet no golden standard 
exist for this. Different software is used in the pipeline, and the 
choice and use of these will determine the output. The approach 
varies between labs and research group, and accordingly the out-
put can differ and potentially lead to different clinical interpreta-
tions. In general, NGS data analysis involves the following steps:  
 
1) Alignment: The sequence reads identified from the sequencing 
process are mapped to the reference genome (Figure 8, Picture 9). 
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Each sequence is mapped to the place on the reference genome of 
which it originates.  
 
2) Variant calling: After alignment, the nucleotide differences be-
tween the patient and the reference genome are identified at a 
given position in the genome. 
 
3) Annotation of variants: Once the variants are identified, each 
variant is annotated. This include that information on the func-
tional effect of the gene, protein sequence, and other information 
from databases such as the Human Gene Mutation Database; 
((HGMD) http://www.hgmd.org/) are listed together with the var-
iant. Importantly, also information on minor allele frequency is an-
notated. In our case the allele frequency was annotated from The 
Exome Variant Server, which is retrieved from the Exome Sequenc-
ing project (ESP), http://evs.gs.washington.edu/EVS/), and the 
1000 Genomes Project.  
 
We used the same validated bioinformatics pipeline to handle the 
sequencing data as is used for clinical samples in the Department 
of Clinical Genetics, Odense University Hospital. For alignment to 
the human reference genome (build hg19) we used the software 
NovoAlign v.3.01 (NovoCraft). For variant calling we used GATK 
Best Practice pipeline c.2.7 (http://www.ncbi.nlm.nih.gov/pub-
med/?term=25431634), and for annotation we used VEP (Variant 
Effect Predictor, http://www.ensembl.org/info/docs/tools/vep/in-
dex.html).  
 
Filtering of a genetic variants  
In our study hundreds of nucleotide differences (genetic variants) 
per patients were identified and annotated. A lot of these variants 
were non-synonymous: a single nucleotide substitution that po-
tentially could affect protein function. In order to find a potentially 
clinically significant variant, some sort of filtering was needed. This 
approach was carefully considered, because at every step of this 
process there was a risk of filtering out variants of significance. The 
used filtering was described in Paper III, but was based on the as-
sumptions that the causal variant would (1) alter the protein cod-
ing sequence and (2) would be extremely rare. Concerning (1) we 
began with filtering out all variants found in introns (except for the 
splice site consensus sequence) and furthermore all synonymous 
variants as they are not expected to change the protein coding se-
quence. Next, concerning (2), we compared the allele frequencies 
with estimated populations frequencies. Thus we filtered out all 
variants with a minor allele frequency occurring in >1% of the pop-
ulations in the 1000 Genomes Project and The Exome Seqencing 
Project (ESP).  
This filtering resulted in a much smaller list of rare, non-synony-
mous genetic variants, which were evaluated carefully. We classi-
fied each of these variants into pathogenicity classes to aid in the 
clinical interpretation. This scheme was inspired by the classifica-
tion described in Plon et al. for the International Research on Can-
cer (IARC) Unclassified Variants Working Group (172). The evalua-
tion of these variants does not particularly differ from those found 
with Sanger sequencing: Some variants will be assumed to be path-
ogenic based on previous reported findings or the nature of the 
mutation e.g. frameshift mutations leading to a premature stop co-
don. Nevertheless, missense variants, splice variants, and UTR var-
iants can be difficult to evaluate and several factors must be taking 
into account. These include the phenotype of the patient, family 
history, segregation analysis in the family, functional studies, pre-
diction tools, previous literature, and allele frequency databases 
(see Figure 9).  
 
In silico prediction tools 
To assist in the evaluation of missense variants, we used three pub-
lic in silico prediction tools, which can predict the effect of non-
synonymous variants: SIFT (sorting the intolerant from the toler-
ant) (http://sift.jcvi.org), PolyPhen-2 (http://genetics.bwh.har-
vard.edu/pph), and AlignGVD (http://agvgd.iarc.fr/). Several tools 
are available, yet SIFT and PolyPhen-2 are two of the most com-
monly used. The prediction tools use different approaches to pre-
dict the effect of the variant, such as the difference in biochemical 
properties between the variant and wild-type amino acid, the evo-
lutionary substitution frequencies between the wild-type and var-
iant amino acid, and evolutionary conservation at the position of 
the variant. This is based on the assumption that biochemical 
changes of a variant are more likely to be disease-causing (or likely 
disease- causing), and that conserved amino acids across species 
are more likely to have an important structural or functional role. 
Furthermore, the prediction tools can take considerations on pro-
tein structure into account (173, 174).  
We choose SIFT, PolyPhen-2, and AlignGVGD, as they have differ-
ent approaches: SIFT combines the conservation of the sequence 
and physical properties as well as consider the amino acid change 
in the structural protein (175). PolyPhen-2 is based on evolutionary 
(phylogenetic) information as well as sequence, and structural fea-
tures of the variant, which is feed to a probabilistic classifier (176). 
Align-GVGD uses multiple protein sequence alignments and the bi-
ophysical characteristics of amino acids (174). In silico tools may 
give a clue to the importance of the variant, but the sensitivity and 
specificity of the tools vary. Thus the evaluation of a missense var-
iant must never be based on prediction tools alone. It is beyond 
the aims of this thesis to go in depth with comparison of the differ-
ent prediction tools, but these have been reviewed in several pa-
pers (173, 177, 178). 
 
Evaluation of splice variants 
The precise recognition of splicing signals is critical and variants af-
fecting splicing comprise a considerable part of pathogenic 
germline mutations. In order to evaluate a splicing variant, the 
most reliable method would be to analyse RNA samples of the pa-
tient, but this is not always possible and was beyond the aim of this 
project. As with missense mutations, several in silico tools that pre-
dict the effect of splicing variants, can give a hint on importance. In 
the evaluation of splice mutations we used the SpliceSiteFinder-
like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing 
Finder. These prediction tools have been evaluated in different re-
views (179, 180).  
 
Figure 9: Different strategies when evaluating genetic variants 
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Variant frequency 
As described, the annotated variants from NGS sequencing were 
filtered using the minor allele frequencies as reported in 1000 Ge-
nomes Project and ESP, which were available at the time of variant 
annotation. But soon after our analysis was finished, the Exome 
Aggregation Consortium (ExAC), Cambridge, MA (URL: 
http://exac.broadinstitute.org) became available. This database 
contains information on results from WES of approximately 
60,0000 unrelated individuals, including the results from the 1000 
Genomes Project and ESP. In ExAC, all data from these projects 
have been reanalysed with the same bioinformatics software and 
pipelines to increase consistency. We used the population fre-
quency from ExAC to evaluate the rare variants that we had de-
tected (Paper III, supplementary table) after initial filtration. It is, 
though, important to note that although ExAC have tried to elimi-
nate the possibility of monogenetic diseases in their study-popula-
tion, some variants may also have incomplete penetrance or po-
tentially be associated with age dependent variable expressivity. 
 
Copy number variation 
The software GATK was used for variant calling, which enable de-
tection of single nucleotide polymorphism and small deletions or 
small insertions. Yet, this software does not allow for detection of 
structural variants or copy number variants. Thus, to detect large 
deletions and duplications we used the software Contra (Copy 
Number Analysis for Targeted Resequencing, http://contra-
cnv.sourceforge.net).  
 
Quality control of NGS 
As presented, NGS is a multiple step analysis and multiple quality 
control checkpoints exist throughout preparation of the library, the 
actual sequencing, the data analysis, and the interpretation. De-
spite its complexity it is relatively easy to identify samples that are 
of insufficient quality (181). A widely used quality score is the cov-
erage of each base, that is how many times has one base been se-
quenced: the more times the less is the risk that a detected variant 
is a sequencing error. Coverage of over 30x per base is an accepta-
ble quality control checkpoint. The target region has to be covered 
nearly 100%. Furthermore, the proportion of reads i.e. forward and 
reverse should be approximately equal. 
 
Validation of findings 
The variants of uncertain pathogenicity were validated with Sanger 
sequencing. Furthermore, a senior expert pathologist reviewed the 
histopathological diagnoses of polyps in enrolled patients.  
 
Limitations 
We gained sufficient quality of our NGS, yet, seen in a larger per-
spective, no genetic analysis is 100% complete. NGS is a complex 
technical analysis and the chosen software can filter out variants 
of importance. Bioinformatic tools may be useful, but this is still far 
from trivial. Segregation of the variant within a family can also be 
helpful in assessing pathogenicity, but factors such as penetrance, 
expressivity, and genetic mosaicism can still limit clear identifica-
tion. The same holds true for frequently observed variants e.g. >1% 
and one cannot completely exclude such variations as being be-
nign. The technique is constantly improving and so is the 
knowledge of our variants. Taking it all in consideration it comes 
down to the question of whether we actually can rule out that the 
patients have a HPS? This is probably not the case. A significant 
part of HPS patients are mutation negative. So whether one or 
more of our patients will develop more symptoms on HPS is un-
known. In patients having more than one HP, only one HP was re-
evaluated by our senior expert pathologist, which could be a prob-
lem because of the interpathologist difference in diagnosis. How-
ever, patients with more than one polyp comprised only five out of 
77 patients. 
 
Strengths 
To date only a few studies have addressed the issue of HPS in pa-
tients with a low or moderate polyp burden (167, 182). We demon-
strated that is was possible to design a gene panel of sufficient 
quality to be used in a clinical diagnostic laboratory. Finally, the his-
topathology of the polyps was also re-evaluated by a pathologist 
increasing the quality of the results.   
 
Methodological considerations: Paper IV  
 
Type of research 
In Paper IV we reported the research participants’ attitude towards 
the disclosure of IFs in NGS-studies. The method is qualitative in its 
nature, but the end-point was rather simple: Did the participant 
want to have (A) information on all IFs, (B) information on actiona-
ble IFs, or (C) no information on IFs at all. 
 
Inclusion and exclusion of participants   
The inclusion for this paper was based on all participants over the 
age of 18 years, with one or more HP, who initially responded to 
participate in the genetic studies as presented in Paper III. Thus all 
participants who were informed about the project and who gave 
consent were included, that was before the type of NGS to be per-
formed (WES or targeted NGS) was decided, and before discover-
ing that a part of the participants had sporadic gastric fundic gland 
polyps. Thus the participants’ answers were not influenced on 
whether they were later excluded from the main project in Paper 
III. This part of the study was approved by additional protocol nr. 4 
to the original protocol numbered S-201220057 by the The Re-
gional Scientific Ethical Committees for Southern Denmark.  
 
The semi-structured interview 
In Paper IV we used the term ”semi-structured interview,” to de-
scribe the interviews with the research participants. The term can 
be broadly interpreted. In this case the term covered that the 
structure and information giving to the participants were framed 
beforehand: a list of questions and topics to be covered during the 
conversation was made e.g. the same examples of untreatable 
conditions (category A) and treatable conditions (category B) were 
given. A semi-structured interview allows for the interviewer to 
have a wide framework, and thus, when giving information in this 
study, the mode of conversation differed from participant to par-
ticipant. 
 
Limitations  
The survey did not include participants less than 18 years of age, 
although this is very relevant in research of genetic diseases of 
which many present in childhood or adolescence. We decided only 
to include participants who were capable of answering for them-
selves, and thus only included participants over 18 years of age. 
Another limitation is that we do not know the reasons for the de-
cisions made by the participants. The majority of our participants 
considered themselves healthy, as there is usually no follow-up 
when one or a few JPs are removed, but other research projects 
may include affected participants, who perhaps have other moti-
vations for participating. Finally, we cannot exclude that a so-called 
“interviewer effect” may influence the answers of the participants 
as the Ph.D.-student conducted all but one of the interviews.  
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Strengths 
The definite strength of the study is that, at the time of publication, 
the opting out possibly on IFs was very much discussed, as the 
guidelines of the American College of Medical Genetics did not 
have that option in their recommendations from 2013 (155). Our 
paper was meant to add to the discussion from a participant’s per-
spective as a lot of surveys before that had been conducted on cli-
nicians, geneticist, and professional’s views. As discussed later, 
other surveys have since been published (183). The strength of the 
semi-structures interview is the possibility of going into depth and 
details with complex topics. Furthermore, the interviewers can ex-
plain views in their own terms.  
 
Methodological considerations: Paper V-VI 
The purpose of Paper V was to collect information on all Danish 
patients with PJS, and in Paper VI to collect information on patients 
with JPS and pathogenic SMAD4 mutations. We aimed to describe 
the disease pattern, genotype, and phenotype. The methodology 
of the papers, that is the strategies for identification of patients 
and gathering of clinical information, was practically the same for 
the two papers, although the use of some specific registers dif-
fered.  
 
Identifications of patients 
The identification of patients was based upon the Danish registers 
and relevant departments. In Paper V we used the DPDB (search 
on PJPs), the Danish National Patient Register, Danish departments 
of clinical genetics, and the Polyposis Register, Hvidovre Hospital, 
Denmark, to identify patients. In Paper VI we used the Danish HHT-
registry and Danish departments of clinical genetics to the identifi-
cation of SMAD4 mutations carriers. In both papers, we asked the 
Danish laboratories performing screening of STK11 and SMAD4 for 
lists of mutation carriers. All patients in the registers are listed with 
their social security number, which enable crosschecking between 
the registers, and enable gathering of further information from the 
patients’ medical files.  
 
The Danish National Patient Register  
The Danish National Patient Register was established in 1977 and 
includes information on all patients admitted to a Danish hospital. 
The register collects information in the form of code (ICD-10) made 
by the clinical departments after a procedure and/or diagnosis. The 
register is very comprehensive but also very complex and its con-
tent have changed over time (184). The validity of this register has 
been investigated and reviewed with mixed conclusions: most 
agree that the register is very good and wide-ranging, but that the 
registered codes added by clinicians are not always  
precise (185, 186). In Paper V we searched for patients with the 
ICD-10 diagnose code for Peutz-Jeghers Syndrome (DQ858B). With 
this search, we identified patients with their social security num-
ber, which we used for further collecting of information. 
 
Collecting medical information 
To collect medical information we used the medical files of the pa-
tients. The files were obtained from relevant departments (surgi-
cal, paediatric, or genetic) throughout the country.  
 
Limitations 
Retrospective studies are always limited by the available infor-
mation on patients. Furthermore, the patients in both article V and 
VI followed different surveillance programs, which makes it diffi-
cult to obtain robust results and compare the patients with each 
another. In Paper V, concerning patients with PJS, some patients 
were born in the first half of the 20th century and it was difficult to 
obtain medical files from this period, thus information about initial 
presentation and early symptoms was not always available.   
 
Strengths 
The strength of both studies is that data based on the Danish reg-
isters offers relatively easy access to identifying patients and col-
lect comprehensive medical information. Therefore it is possible to 
make nationwide studies of this type. The work also forms the ba-
sis for further studies on the patient groups.  
 
RESULTS  
 
Paper I: Juvenile polyps in Denmark from 1995-2014 
We used the DPDB to collect information on all histopathologically 
examined JPs from 1995 to 2014. A total number of 2108 JPs in 
1772 patients was examined in the period, of which approximately 
25% were from children. We calculated the incidence of JPs to be 
between 1:45,000 to 1:65,000. Most patients (n=1666) in the study 
period had a single JP removed. The mean age at diagnosis was 
37.9 years of age. JPs were detected in the rectosigmoid colon in 
82.9% of adult cases and 94% of children cases. Approximately 1% 
of the patients fulfilled the diagnostic criteria of JPS having more 
than five JPs. 
 
Paper II: Hamartomatous polyposis syndromes: A review  
In this paper we conducted a review of the HPS based on the cur-
rent literature.  
 
Paper III: Germline variants in Hamartomatous Polyposis Syn-
drome-associated genes from patients with one or few 
hamartomatous polyps 
We created a panel of 26 genes associated with HPS and other GI 
cancers, and analysed DNA from 77 included patients. The quality 
of the method was sufficient, as we obtained a mean coverage of 
the target region of 2222x (range: 459x - 4593x). For all patients 
99.97% of the bases in the target region had a minimum coverage 
of 30x, which is acceptable. We detected several germline variants 
and among them were three in ENG, two in BMPR1A, one in PTEN, 
and one in SMAD4. None of the detected variants could be classi-
fied as definitively pathogenic (Class 5) or likely pathogenic (Class 
4) according to our variant classification scheme. Furthermore, we 
observed a significant interpathologist difference in evaluation of 
polyp type, as 30% of the JP diagnoses in the enrolled patients 
could not be confirmed.  
 
Follow-up in patients with variants of uncertain pathogenicity   
During the genetic analysis we detected some variants of uncertain 
pathogenicity, which could have clinical implications for the pa-
tients. This was only in a few cases, but the families were contacted 
for additional clinical information, and, in some cases, additional 
analyses. The decision on which variants to follow up on, was based 
on the phenotype-genotype correlation of the gene in which the 
variant was detected, predictions tools, and the allele frequency.  
We have until now followed up on these detected variants: 
   
ENG:c.374T>C, p.Val125Ala: The patient had one JP diagnosed with 
colonoscopy as an adult, and no family history of HHT symptoms, 
cancer, or polyps. The patient was offered clinical examination for 
symptoms of HHT. The examination was negative. We concluded 
that the variant was likely not pathogenic.  
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AKT1:c.719C>G, p.Ser240Cys: The patient had one JP diagnosed as 
a child. During the research period, the patient had been referred 
to genetic counselling for unspecific neurological symptoms. An ex-
pert neurologist could not confirm these. The phenotype-genotype 
correlation of AKT1 is still unclear. We concluded, based on our 
current knowledge, that the variant had no clinical implications for 
the patient.  
 
CDH1: c.2335C>T, p.Arg779Trp: The patient had one JP diagnosed 
in adolescence. The family was contacted for further clinical infor-
mation and to obtain a family history of cancer. Family history re-
vealed no history of breast cancer or ventricular cancer. Samples 
from the parents revealed that the variant was inherited from the 
father, who is healthy. The evaluation of the family is on going.   
 
BMPR1A c.1327C>T, p.Arg443Cys: The family was contacted in 
writing to gather further information on family history, and to offer 
genetic testing of the parents for this variant of uncertain patho-
genicity, but the family has not responded.   
 
Paper IV: Research participants in NGS studies want to know 
about incidental findings 
The 127 research participants were asked to decide whether 
he/she wanted to receive information on IFs in three categories: 
(A) To receive disclosure of all IFs, that might be found during the 
research period – even if the variant leads to risk of an untreatable 
or unpreventable disease. (B) To receive disclosure on IFs only if 
the variant leads to a condition that is treatable, preventable, or 
for which there can be offered surveillance. (C) Not to receive dis-
closure on IFs at all. The majority of participants wanted disclosure 
of all IFs (A) (n=78 (61%)). 45 participants wanted disclosure of ac-
tionable variants (B) (36%), Four participants (3%) did not want to 
receive information on IFs at all (C). There was no significant differ-
ence in the answers relating to sex or age. 
 
Paper V: Disease pattern in Danish patients with Peutz-Jeghers 
Syndrome  
We identified 43 Danish patients with PJS through Danish registers, 
relevant hospital departments, and laboratories. We included 43 
patients of which 14 had deceased. The male:female ratio was 
26:17. We estimated the prevalence of PJS to be approximately 1 
in 195,000 individuals. The median age at diagnosis was 29 years 
(10 month to 67 years) with obstruction of the small bowel as the 
most frequent presenting symptom seen in 35% of PJS patients. 
Approximately 50% of the study population had a family history of 
PJS related symptoms. We noted 18 occurrences of cancer at vari-
ous anatomical sites. The included patients showed great variabil-
ity in phenotypic expression. 
 
Paper VI: JP-HHT phenotype in Danish patients with SMAD4 mu-
tations 
We identified 14 Danish patients with pathogenic SMAD4 muta-
tions through the Danish departments of clinical genetics, the Dan-
ish HHT-registry, and Danish laboratories carrying out SMAD4 anal-
ysis. All patients had polyps removed and 11 out of 14 fulfilled the 
diagnostic criteria for JPS. Eight patients were screened for HHT 
symptoms and seven of these fulfilled the HHT (Curaçao) criteria. 
One patient had aortic root dilation.  
 
GENERAL DISCUSSION 
The aim of the research was to expand the knowledge on clinical 
course and molecular genetics in patients with HPs and the HPS, as 
well as investigating research participants’ attitude towards the re-
sults of extensive genetic testing. This was obtained by investigat-
ing the occurrence of JPs (Paper I), to perform a literature review 
(Paper II), to test the hypothesis that a subgroup of patients with 
one or few HPs may have HPS with the use of genetic testing (Paper 
III), to investigate research participants views towards opting out 
on information on incidental genetic findings in NGS studies (Paper 
IV), and finally to collect clinical and genetic information on all Dan-
ish patients with PJS and SMAD4 mutations (Paper V-VI).  
 
Management of juvenile polyps in the GI tract 
The presented research, in addition to current literature, allows us 
to suggest how to manage the finding of JP(s) in the GI tract. In 
Figure 10 and Figure 11 we present a possible approach after de-
tection of JP(s) in children and adults, respectively.  
 
Children: In Paper I we estimated that approximately 20 Danish 
children per year are diagnosed with a JP. Because of the possibility 
of detecting further JPs proximal to the rectosigmoid, the child 
should always be offered colonoscopy if the JP(s) initially has been 
detected otherwise (14-16). Most children have a single JP (17, 18), 
and the first question is how to separate children with a single JP 
from those with JPS or another HPS. Although cancer in HPS devel-
ops in adulthood, the diagnosis of a HPS in early life establishes the 
possibility of surveillance and identification of at-risk members of 
the families. Most cases of HPS present in childhood or adoles-
cence, and special caution should be taken in these age groups, but 
the phenotypic heterogeneity is wide and some present in infancy 
and some in (late) adulthood. As shown in Paper VI some patients 
with pathogenic SMAD4 mutations have very few polyps and the 
phenotypic expression varies even within the same family. Thus 
the distinction between a patient with one or few JPs and JPS/HPS 
is blurred. To add further to the confusion some have used a work-
ing definition of three or more JPs (187, 188) in JPS and not five or 
more (the Jass criteria)(189). We did not find that genetic testing is 
relevant in children with a single JP (Paper III), but we suggest that 
the clinician should evaluate family history of polyps and cancer as 
well as look for and ask for extraintestinal manifestations such as 
dermatological manifestations, intellectual disability etc. At this 
point it is important to consider that approximately 50% of cases 
are de novo and family history may be negative. Other information 
such as the age of the child could also be taken into considerations 
as a single JP often present at a younger age than JPS and that 
anaemia is more common in patients with JPS than with a single JP 
(11, 18).  
If nothing supports the diagnosis of HPS, the next question is 
whether the child should be offered clinical follow up with endos-
copy in order to detect recurrent polyps. This is not a simple ques-
tion and no evidence-based guidelines exist at the moment. Previ-
ous studies are small and sometimes include other polyp types 
than JPs. Thus the recurrence is hard to determine. Fox et al. inves-
tigated a cohort of 192 children with JPs, including 117 with a single 
JP, detected with colonoscopy. Eighteen children with a single JP 
were followed up with endoscopy, and three had recurrence (17). 
Based on this recurrence rate the authors argued that children who 
present with a single polyp should be followed up with endoscopy 
(17). The authors also found neoplasia in 3.9% of the investigated 
polyps in the whole cohort (17). Any recommended surveillance 
programme with colonoscopy in this group of patients has to be 
weighed against the drawbacks and risks in addition to the cost-
effectiveness. The introduction of colonic video capsule endoscopy 
may change this in the future. But as such, at the moment, there is 
no strong evidence to support that clinical follow-up is necessary.  
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The finding of multiple JPs, 2-5 JPs, is a special challenge because 
of the difficult distinction from JPS. As NGS are implemented, the 
threshold for doing genetic testing can be lowered, and genetic 
testing could be considered. Further evaluation of the patient 
should at least include exploring family history and extraintestinal 
findings as presented in Figure 10.  
 
 
Figure 10: Proposed algorithm when detecting one or more JP(s) in 
children 
 
Adults: In Paper I, we calculated an incidence of detected JPs of 
approximately 1:40,000 to 1:65,000 per year, with 75% being de-
tected in adults. Though rarely, adults are still being diagnosed 
with JPs and the same questions as in children can be asked: Is 
there any signs of JPS/HPS? And should the patient be followed up 
with endoscopy? Even fewer studies of the natural history and 
 
 
Figure 11: Proposed algorithm when detecting one or more JP(s) in adults 
 
recurrence exist of JPs in adults, but as HPS mainly manifest in 
childhood and adolescence the finding of a single JP should not 
necessarily lead to such extensive investigations as in children. The 
reason for referral should be considered: Is the JP an incidental 
finding? Family history, the age of the patient, previous history of 
polyps, or cancer should be considered. The finding of 2-5 polyps, 
perhaps in addition to polyps of another histopathological type, 
should lead to suspicion of a JPS or mixed polyposis syndrome. As 
in children genetic testing could be relevant at this point. The his-
topathological type of polyps should also be taken into considera-
tion: Adenomas are frequent in adults; however, inflammatory 
polyps are rare and could be mistaken for a JP.  
 
Management of Peutz-Jeghers polyps in the GI tract 
The finding of a PJP at any age should always be followed up by 
further examinations, as cases of solitary PJPs are rare. Colonos-
copy, gastroscopy, and small bowel screening with MR-enter-
oclysis, MRE, or VCE should be performed as well as genetic testing 
for STK11 mutations. A thorough family history of polyps, cancer, 
rectal bleeding, and bowel obstruction should be obtained. History 
of mucocutaneous pigmentations, which importantly tend to fade 
after puberty, should be considered. Genetic analysis is a helpful 
tool in the diagnostic process as mutations in STK11 are found in 
over 90% of patients fulfilling the diagnostic criteria for PJS (69). 
The clinical significance of solitary PJPs without PJS is debated, 
though reports of such cases exist (19-21). Some authors have sug-
gested that having a single PJP should be regarded as a separate 
clinical entity (21), while others disagree: Burkart et al. studied 
eight cases of solitary PJPs, and found that all patients had some 
indications of PJS when reviewing clinical information or family his-
tory (22). Burkart et al. then argued, that the occurrence of a single 
PJP presumably does not exist and at least the patients have the 
same risk of cancer as those with PJS (22). Furthermore, as shown 
in Paper V, the expressivity and age of diagnosis of PJS is very wide 
(10month-67y). If the patient after thorough examination does not 
have further polyps or indications of PJS, one should consider re-
vising the histology of the polyp, and if the pathology is confirmed 
one should still consider clinical surveillance. A proposed algorithm 
for follow-up is presented in Figure 12.  
 
 
 
Figure 12: Proposed algrithm when finding one or more PJP(s). MRE=MR-
enterography/MR-enteroclysis. VCE= video capsule endoscopy  
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Surveillance – does it help?  
Although NGS may elucidate further genetic causes of HPS, one can 
ask: What follows diagnosis? What do we offer family-members at 
risk? What kind of surveillance is relevant and does it help? The 
answers are far from simple: The purpose of surveillance in JPS and 
PJS patients is to detect cancer in early stages and to avoid morbid-
ity in relation to severe polyposis. Clinical guidelines have been 
proposed (58, 62, 91), but the evidence for these guidelines is 
sparse, and most are based on expert opinions (the lowest degree 
of evidence, level D) or evidence level C, low (62, 91) e.g. in PJS and 
JPS only a few papers have described the long-term outcome of GI 
surveillance including surgery in relatively small patient popula-
tions (44, 63, and 13 patients) (72, 190, 191). All three studies were 
retrospective in their design, and it is important to note that previ-
ous publications are subjected to the risk of referral bias, publica-
tion bias, and ascertainment bias, which must always be taken into 
consideration before making any conclusions based on the current 
knowledge. In order to establish stronger evidence more studies, 
with larger patient and control groups are needed. Studies of the 
underlying mechanisms of cancer development are also missing. In 
Denmark, no consensus guidelines for surveillance of PHTS, PJS, 
and JPS exist, although we discussed JPS guidelines in a Danish con-
text some years ago (192).  
 
The histopathological aspects of HPS 
One significant finding in our studies (Paper VI) was that HPS pa-
tients seem to have a wide variety of histopathological types of GI 
polyps, and that the histopathological diagnosis is not always clear 
(Paper III). In Paper III the diagnosis of a HP could not be confirmed 
in 30% of cases by our experienced gastropathologist. Others have 
described this interpathologist discrepancy as well as the wide 
range of polyp types seen in JPS patients (32, 75, 167). When a di-
agnosis of e.g. PJS or JPS is based on only a few polyps a ”misclas-
sification” of polyps may led to the wrong diagnosis and in some 
cases delay important follow-up for the patient and their families 
as found in Aretz et al. (75) Thus it is important to examine a large 
enough number of polyps in order to determine the predominant 
type (52), but if the patient only has few polyps (as we saw in some 
patients in Paper V and VI) this is not always possible and other 
information e.g. family history should be taken into account.  
 
The role of genetic analysis in HPS diagnostics 
As HPS, with the exception of Cronkhite-Canada Syndrome, is 
caused by germline mutations, genetic analysis can be used to aid 
diagnostics, but the finding of a pathogenic mutation is not (al-
ways) part of the criteria for HPS. This, in addition to the fact that 
mutations are not found in all patients with HPS, emphasizes the 
importance of the clinical evaluation. We did not, based on genetic 
analysis, confirm our hypothesis in Paper III: that patients with one 
or a few polyps may have HPS, but we did create a gene panel and 
performed NGS of sufficient quality to be used in a clinical diagnos-
tic setting. It is indisputable that the increasing use of NGS has 
made genetic testing much cheaper and opens up possibilities in 
assisting the clinicians in the diagnostic evaluation to a larger ex-
tent than just a few years ago. Yet, one must still consider the im-
plication of finding a pathogenic or a variant of uncertain patho-
genicity for the patients and their relatives. Genetic counselling 
should be a cornerstone in the management of HPS patients, both 
in families with or without a known pathogenic mutation as well as 
in de novo patients.  
 
 
 
Evaluation of genetic variants 
The data analysis and evaluation of variants in Paper III highlight 
the difficulty in interpreting the significance of germline variants 
generated from genetic analysis, even in genes with a well-estab-
lished role in HPS pathogenesis. All who perform NGS, which gen-
erates information on several variants of uncertain pathogenicity, 
faces this challenge. A particular problem with the evaluation of 
pathogenicity is the usage of previous results: Genetic studies 
based on Sanger sequencing were often based on single cohort 
studies of symptomatic populations and may be erroneously asso-
ciated with disease due to small cohort sizes, limited validation 
studies, and unmatched control populations (193). This was illus-
trated by Dorschner et al. who investigated 114 genes in 1000 in-
dividuals and identified 239 variants listed as disease-causing in 
HGMD. The authors evaluated these variants with allele frequency 
and literature reviews, and found only 16 autosomal-dominant 
variants to be pathogenic or possibly pathogenic (194). This paper 
also illustrated that NGS with WES has offered a new dimension to 
variant evaluation, as it is now possible to investigate large healthy 
and non-healthy populations allowing us to compare the detected 
variants with the frequency in the general population. Thus pro-
jects such as the 1000 Genomes Project, ESP, and ExAC have indi-
cated that germline variants including deleterious variants are 
more frequent in healthy individuals than earlier anticipated (193, 
195). Another example is Bodian et al. who investigated 681 indi-
viduals of reproductive age with no history of cancer in the family. 
When performing NGS sequencing in 158 cancer related genes, the 
authors found that every individual carried multiple non-synony-
mous variants with an average of 68 variants per person (196). Alt-
hough, we did not report any likely or definitively pathogenic vari-
ants in Paper III, we do not know whether the variants of uncertain 
pathogenicity are a contributing factor to polyp formation or 
whether we in the future, with further knowledge, may evaluate 
the variants differently.   
 
Genotype-phenotype correlations 
Genotype-phenotype correlations studies are important in eluci-
dating the HPS further; these studies can shed new light on the 
pathophysiological mechanisms of the syndromes and aid in the 
development of more individualized surveillance programs. In Pa-
per VI we showed that extra attention must be paid to patients 
carrying a SMAD4 mutation as these patients may have potential 
severe manifestations of their disease: thus several had both a 
heavy polyp burden and HHT manifestations with potential life-
threatening AV-malformations, and aortopathy was seen in one 
patient. The fact that SMAD4 mutations carriers have a “broader” 
phenotype may be explained by the central position of SMAD4 in 
the TGF-β pathway, see Figure 6. To add further to the picture of 
SMAD4 it is interesting that patients with Myhre Syndrome, char-
acterized by intellectual disability, dysmorphic facial features, and 
skeletal anomalies, also harbour a de novo mutations in SMAD4 
(197). Mutations in SMAD4 have also been detected in patients 
with LAPS syndrome (characterized by laryngotracheal stenosis, ar-
thropathy, prognathism, and short stature syndrome), suggesting 
that Myhre syndrome and LAPS are a clinical entity with variable 
expression (198). The effect of the altered protein function in pa-
tients with Myhre Syndrome, LAPS, and JP-HHT patients must be 
different, but this illustrates that we still have a lot to learn. Yet, 
the rarity of these syndromes makes it difficult to gather large pa-
tient populations. Nationwide studies, and preferably international 
co-operations, are necessary in the future. 
Interestingly, in Paper III, we also detected variants in ENG. Patho-
genic mutations in this gene are detected in approximately 40-50% 
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of HHT patients (199). ENG also works in the TGF-β signalling path-
way, and previous studies have reported germline variants in ENG 
in polyposis patients (167, 182, 200). Whether these mutations are 
insignificant, causative, or perhaps a contributing factor to polypo-
sis is unknown.  
 
New candidate genes 
With the available techniques and knowledge it is not possible to 
detect germline mutations in all HPS patients: 20-40% of JPS pa-
tients, 5-10% of PJS patients, and at least 50% of patients with CS 
are mutation negative. One can hypothesise that this is either be-
cause of limitations in our technique or that the conditions show 
genetic heterogeneity. Some patients can also be mosaic for the 
causative mutation and thus the mutation may not be detected in 
a blood sample. In the last years it has been shown that other mu-
tations than PTEN is causative of CS or CS-like phenotype: germline 
mutations in SDHB and SDHD in patients with CS and a CS-like syn-
drome have been reported (201) as well as a germline hypermeth-
ylation of KLLN (202). Another 8.8% of unrelated CS patients with-
out germline PTEN mutations were found to have germline PIK3CA 
mutations and 2.2% had germline AKT1 mutations (203). The de-
velopment of WES, although there are still limitations to this 
method, offers a great possibility of investigating mutation nega-
tive patients. This approach was used in Ngeow et al. who recently 
identified a new susceptibility locus for HPS as they detected a 
germline missense mutation in SMAD9 in a patient with JPS associ-
ated with Gl ganglioneuromas (204). 
 
HPS pathogenesis and influencing factors 
The underlying molecular mechanisms in cancer development in 
HPS are largely unknown. As addressed in the background and in 
this discussion we need a far better understanding of the molecu-
lar details in order to understand these conditions. A somatic sec-
ond hit theory seems intriguing as an elegant explanation of polyp 
formation or cancer development, and though some studies have 
supported this (137), the results are far from conclusive. Studies on 
this matter are also limited by sample size and inconsistencies in 
the used techniques e.g. some have used mutation analysis, mi-
crosatellite markers, hypermethylation analysis, and immuno-
histochemistry for investigations of the molecular changes. Fur-
thermore, we still need an explanation for the extraintestinal 
manifestations as seen in e.g. JPS or CS. These specific anatomical 
sites are subjected to tissue specific genetic factors, and several 
environmental factors or epigenetic factors may also play a role. 
NGS opens up the possibility of studying somatic mutations in 
polyps and carcinomas to a greater extent than previous.  
 
Ethics of NGS  
The development in genetics has been explosive: the first human 
genome required 13 years to sequence and did cost nearly 3 billion 
dollars. In contrast, today, several genomes can be sequenced in 
one day for approximately 1000 dollars each. However, the 
knowledge of what the genes actually do and how they interact 
with each other and other proteins is still lagging. We generate a 
lot of data, that we do not understand and concurrently we face 
ethical questions as how to manage the data and what to tell the 
patient and the families. The ethical discussion, which has followed 
the integration of NGS into clinical practise, has raised several 
questions. Ethical views are founded in culture and on religious be-
liefs, personal experience, and legal as well as moral obligations, 
and the questions are hard to agree upon. Yet, the debate in itself 
also supports the idea of genetic exceptionalism: that genetic re-
sults somehow should be treated differently from other clinical in-
formation. But is genetic testing any different than performing e.g. 
an MR scan of the brain in the case of headache? The risk of IFs is 
still present. Green et al. concluded that at least in the case of pre-
dictive testing no clear, significant distinctions between genetic 
and non genetic tests justify a different approach than with other 
clinical testing, and that predictive testing does not alter the obli-
gations of physicians e.g. not to harm unnecessarily (205). But still 
it is important to be aware of other aspects of genetic testing such 
as predictive testing of minors, implications of the test result for 
other family members, and theoretical risks of insurance or em-
ployment discrimination. In Paper IV we addressed a specific issue 
of the opting out possibility when performing NGS and showed 
that at least most research participants are “not afraid” of infor-
mation. Almost simultaneously with our study a similar, though 
much larger study, was published. In a web-based survey Middle-
ton et al. investigated the views of the public as well as genetic re-
searches and professionals and found the same tendency as us: 
That members of the public were positive towards gaining infor-
mation on genetic results (183). The study also demonstrated that 
genetic health professionals had a significantly more conservative 
view. Middleton et al. conclude that their finding illustrates a dis-
connection between the views of those handling the findings of re-
search and those participating in research (183). Whether or not, 
and how to decide what information to return to the patient/par-
ticipant is difficult. The ethical discussion will continue and some-
how must be modified by reality; in a few years we will have more 
experience in how to handle information and have an idea of the 
extent of the issues.  
 
 
CONCLUSIONS 
This thesis presents some of our research over the last 3-4 years on 
HPs and HPS. In the six papers we obtained several results to fulfil 
our aims, which was to expand the knowledge on clinical course 
and molecular genetics in patients with HPs and HPS, and to inves-
tigate research participants’ attitude towards the results of exten-
sive genetic research.  
In Paper I we investigated the occurrence of JPs in a 20-year period. 
Based on the registered histologically examined JPs, we found a to-
tal number of 2108 JPs in 1772 patients, of which approximately 
25% were in children. Most patients had a single JP and the mean 
age of diagnosis was 37.9 years of age, in children 5.7 years. 
Though the risk of cancer in HPS is well documented, the risk of 
cancer when having one or few HPs is unknown, and the clinicians 
are faced with the clinical question of how to separate patients 
with few HPs from patients with HPS. In cases of only one or few 
HP(s), we did not find evidence to support the use of additional 
genetic testing in order to diagnose a HPS (Paper III). But in Paper 
VI, where we collected clinical information of SMAD4 mutation car-
riers, we observed that at least some patients with one or a few 
polyps have a pathogenic mutation associated with HPS. Diagnosis 
of HPS is essential, as patients should be offered surveillance of the 
GI tract, but also at other extraintestinal sites, and genetic coun-
selling. Hence, family history and considerations of extraintestinal 
symptoms are essential in evaluating patients with one or few HPs.  
The inter- and intrafamiliary variability in expression was also re-
flected in Paper V where we studied Danish patients with PJS. We 
identified 43 patients, who fulfilled the diagnostic criteria. The me-
dian age at diagnosis was 29 years, with some being diagnosed in 
infancy and early childhood, and some in the sixth decade of life. 
Small bowel obstruction was the most frequent presenting symp-
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tom seen in 35% of JPS patients. We noted 18 occurrences of can-
cer at various anatomical sites and thereby showing that PJS pa-
tients are predisposed to not only cancer in the GI tract but also at 
extraintestinal sites. 
Although the use of genetic testing is increasing as new technolo-
gies develop, we did underline the difficulty in integrating NGS in a 
clinical setting in Paper III and Paper IV: interpretation of genetic 
variants is difficult and furthermore there are several ethical issues 
to consider. Nevertheless, as we concluded from Paper IV, it seems 
that at least research participants are not afraid of genetic infor-
mation: The majority of participants (61%) wanted disclosure of all 
incidental genetic findings and 36% wanted disclosure on actiona-
ble incidental findings.  
 
FUTURE PROJECTS AND PERSPECTIVES  
The presented studies investigated research questions and hypoth-
eses on HPs and HPS. There are still a lot of unanswered questions, 
and the future will show how the rapid development in genetic 
techniques can assist in answering some of these. Our research and 
those of others form the basis for future projects and perspectives 
of which I will mention some here:  
 
Cancer development in HPS 
One of the most intriguing questions is the uncovering of the un-
derlying pathophysiology in cancer development in HPS. NGS 
opens the possibility of studying somatic mutations in both polyps 
and cancer to a larger extend than so far. And although such inves-
tigations may be problematized by the possibility of multiple dif-
ferent cell lines in both polyps and cancer, we may gain evidence 
for or against a hamartoma-adenoma-carcinoma sequence by such 
studies. In the long perspective knowledge of molecular alterations 
in cancers from HPS patients may help in individualizing cancer 
treatment.  
 
Evidence for surveillance 
Surveillance programs for HPS are based on low or limited quality 
of evidence and often on expert opinions. To gain evidence larger 
groups of patients and controls are needed. Because of the rarity 
of the syndromes international cooperation seems rational. In ad-
dition, the basic information on the phenotype of the HPS is still 
sparse, and further phenotypic description and studies on geno-
type-phenotype correlations are valuable in order to describe the 
clinical course, also in patients who are less affected.  
 
Medical treatment? 
The management of HPS has so far been symptomatic. As de-
scribed, STK11 mutations cause dysregulation of the mTOR path-
way resulting in a missing inhibition of the pathway. A drug, Ra-
pamycin, has been developed that works by regaining inhibition of 
the pathway. Rapamycin has been tested in STK11 knock-out mice 
and was found to decrease tumour burden, polyp size, and vascu-
larization (206-208). As we gain more knowledge on the molecular 
mechanisms and cancer development, we might be able to de-
velop targeted therapies for the treatment of HPS in the future.  
 
SUMMARY  
Hamartomatous polyps (HPs) in the gastrointestinal tract are rare 
compared to other types of gastrointestinal polyps, yet they are 
the most common type of polyp in children. The symptoms are usu-
ally rectal bleeding, abdominal pain, obstipation, anaemia, and/or 
small bowel obstruction. The polyps are typically removed concur-
rently with endoscopy when located in the colon, rectum, or stom-
ach, whereas polyps in the small bowel are removed during push-
enteroscopy, Device-assisted enteroscopy, or by surgery. HPs can 
be classified as juvenile polyps or Peutz-Jeghers polyps based on 
their histopathological appearance. Patients with one or a few ju-
venile polyps are usually not offered clinical follow-up as the 
polyp(s) are considered not to harbour any malignant potential. 
Nevertheless, it is important to note that juvenile polyps and HPs 
are also found in patients with hereditary Hamartomatous Polypo-
sis Syndromes (HPS). Patients with HPS have an increased risk of 
cancer, recurrences of polyps, and extraintestinal complications. 
The syndromes are important to diagnose, as patients should be 
offered surveillance from childhood or early adolescence. The syn-
dromes include Juvenile Polyposis Syndrome, Peutz-Jeghers Syn-
drome, and the PTEN hamartoma tumour syndrome. Currently, the 
HPS diagnoses are based on clinical criteria and are often assisted 
with genetic testing as candidate genes have been described for 
each syndrome.  
 
This thesis is based on six scientific papers. The overall aim of the 
studies was to expand the knowledge on clinical course and molec-
ular genetics in patients with HPs and HPS, and to investigate re-
search participants’ attitude towards the results of extensive ge-
netic testing 
 
Paper I: In the first paper we investigated the occurrence, anatomic 
distribution, and other demographics of juvenile polyps in the co-
lon and rectum in Denmark from 1995-2014. Based on the Danish 
Pathology Data Bank we found that 1772 patients had 2108 JPs ex-
amined in the period, and we calculated the incidence of juvenile 
polyps to be between 1:45,000 and 1:65,000. The majority of pa-
tients with juvenile polyps were adults and 1% fulfilled to diagnos-
tic criteria of JPS. The majority of patients had a single juvenile 
polyp.  
 
Paper II: In this paper we conducted a review of the HPS based on 
the current literature. 
 
Paper III: We investigated the hypothesis that patients with one or 
few HPs may have a HPS based on genetic screening. We designed 
a panel of 26 genes associated with HPS and used targeted Next 
generation sequencing in 77 patients with mainly one juvenile 
polyp. We detected several germline variants, among them three 
in ENG, two in BMPR1A, one in PTEN, and one in SMAD4. Although 
some of the detected variants have been reported previously none 
could be classified as definitely pathogenic or likely pathogenic ac-
cording to our variant classification scheme and thus we concluded 
that genetic screening of patients with one or few JPs are not indi-
cated.  
 
Paper IV: In Paper IV we investigated one of the ethical aspects of 
Next generation sequencing: the issue whether research partici-
pants in NGS studies should be offered the possibility of not receiv-
ing information on incidental genetic findings (the “opting out pos-
sibility”). We conducted semi-structures interviews in 127 research 
participants, and found that the majority (61%) wanted infor-
mation on all incidentals findings, while 36% wanted information 
on actionable incidental findings. Only 3% did not want infor-
mation on incidental findings at all. 
 
Paper V: In this paper we wanted to gather information on all Dan-
ish patients with Peutz-Jeghers Syndrome in order to investigate 
the phenotype and genotype. Through Danish registers we de-
tected 43 patients of which 14 had deceased. We calculated the 
prevalence of Peutz-Jeghers Syndrome to be approximately 1 in 
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195,000 individuals. The median age at diagnosis was 29 years with 
obstruction of the small bowel as the most frequent presenting 
symptom. We noted 18 cancer occurrences in the population in 
both the GI tract and at extraintestinal sites, demonstrating that 
these patients are predisposed to cancer at various anatomical 
sites. The study also underlined the wide phenotypic expression of 
the syndrome.  
 
Paper VI: In the last paper we identified patients with Juvenile Pol-
yposis Syndrome, who carry a SMAD4 mutation, and described 
their genotype and phenotype. We especially investigated 
whether these patients have symptoms of both Juvenile Polyposis 
Syndrome and Hereditary hemorrhagic telangiectasia. We identi-
fied 14 Danish patients. Most of these had symptoms of both con-
ditions and one had aortic root dilatation. Thus this group of pa-
tients requires a multidisciplinary follow-up program. 
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